Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | Director | June 12, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2029-06-11 | Direct | 9,000 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 9,000 · Balance 9,000 F1: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2029-06-11 | Direct | 12,700 |
Reported balance
After 2019-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-12 · Grant · Acquired 12,700 · Balance 12,700 F2: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.).
F2: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2019 Filed Jun 14, 2019 20:34 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 12,700 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012102 · rdgdoc.xml · derivative · entry 2 Markham Richard J · CIK 0001362743 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2029-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:34 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012102 · rdgdoc.xml · derivative · entry 1 Markham Richard J · CIK 0001362743 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:26 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantCommon Stock | 30,793,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008683 · doc1.xml · nonDerivative · entry 1 Markham Richard J · CIK 0001362743 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,793,670 F1 · price: Consists of 30,793,670 aggregate shares of Aviragen Therapeutics, Inc. ("Aviragen") common stock received by Care Capital Investments III, LP ("Investments III") and Care Capital Offshore Investments III, LP ("Offshore III") upon conversion of shares of Vaxart, Inc. ("Vaxart") in connection with the merger of Vaxart into Agora Merger Sub, Inc., a wholly owned subsidiary of Aviragen (the "Merger"). In connection with the closing of the Merger, each share of Vaxart common stock was converted into 0.2211 shares of Aviragen common stock. On the closing date of the Merger, the closing price of Aviragen's common stock was $0.82 per share. Following the Merger, Aviragen effected a reverse stock split at a ratio of one new share for every eleven shares of Aviragen common stock outstanding. The effects of such reverse stock split is not reflected here. F2 · ownership.nature: Consists of (i) 30,287,856 shares held by Investments III and (ii) 505,814 shares held by Offshore III. Care Capital III LLC is the general partner of Investments III LP and Offshore III (collectively, "Care Capital") and as a result, Care Capital III LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. The reporting person, Jan Leschly, Jerry N. Karabelas and David R. Ramsay are the four managing members at Care Capital III LLC, and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Care Capital. The reporting person is a managing member of Care Capital III LLC, and serves as a representative of Care Capital on Aviragen's board of directors. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.